Merck & Co Inc (MRK): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Merck ( MRK) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.1%. By the end of trading, Merck rose $3.24 (6.5%) to $53.12 on heavy volume. Throughout the day, 37,150,422 shares of Merck exchanged hands as compared to its average daily volume of 12,248,500 shares. The stock ranged in a price between $50.79-$53.44 after having opened the day at $50.90 as compared to the previous trading day's close of $49.88. Other companies within the Drugs industry that increased today were: Alnylam Pharmaceuticals ( ALNY), up 40.9%, Rexahn Pharmaceuticals ( RNN), up 40.4%, Oragenics ( OGEN), up 32.4% and Hemispherx Biopharma ( HEB), up 24.1%.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $144.7 billion and is part of the health care sector. The company has a P/E ratio of 33.2, above the S&P 500 P/E ratio of 17.7. Shares are down 0.3% year to date as of the close of trading on Friday. Currently there are 5 analysts that rate Merck a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Intercept Pharmaceuticals ( ICPT), down 18.3%, Conatus Pharmaceuticals ( CNAT), down 17.3%, Geron Corporation ( GERN), down 13.8% and Corcept Therapeutics ( CORT), down 13.1% , were all laggards within the drugs industry with Gilead ( GILD) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts